

# Clinical trials of high-dose clopidogrel

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 stent

Trial	Treatments	Patients	Trials design and methods
<b>high-dose clopidogrel vs normal-dose clopidogrel</b>			
<a href="#">GRAVITAS , 2011</a> [NCT00645918] n=1109/1105 follow-up: 6 months	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU $\geq$ 230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	Parallel groups open North America

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>
- dual antiplatelet therapy for stent in all type of patients at <http://www.trialresultscenter.org/go-Q578>

## References

### GRAVITAS, 2011:

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011 Mar 16;305:1097-105 [21406646] [10.1001/jama.2011.290](https://doi.org/10.1001/jama.2011.290)

## 2 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>high-dose clopidogrel vs normal-dose clopidogrel</b>			
<a href="#">GRAVITAS , 2011</a> [NCT00645918] n=1109/1105 follow-up: 6 months	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU $\geq$ 230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	Parallel groups open North America

More details and results :

- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>
- antithrombotics for percutaneous coronary intervention in patients with high residual platelet activity on clopidogrel at <http://www.trialresultscenter.org/go-Q469>

## References

### **GRAVITAS, 2011:**

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011 Mar 16;305:1097-105 [21406646] 10.1001/jama.2011.290

Entry terms: clopidogrel, Plavix, Iscover